Lakefront Biotherapeutics NV current report, Q2 FY2017

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of April 2017, specifically dated April 4, 2017. The registrant is a foreign private issuer incorporated in Belgium, with its principal executive office in Mechelen. The filing serves to incorporate a press release (Exhibit 99.1) into the company's Registration Statements on Forms F-3 and S-8.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a press release and does not contain a financial statement or quarterly results summary.

Material Changes

No material financial changes versus a prior comparable period are detailed in this filing text. The document references a press release issued on April 4, 2017, but the content of that release is not included in the provided text, except for a specific exclusion regarding a quote by Dr. Walid Abi-Saab.

Guidance, Outlook, and Risks

The filing text does not contain management commentary, financial guidance, outlook, or a discussion of risks and contingencies. It strictly confirms the incorporation of an external press release by reference.

Investor Verification Checklist

  • Verify the actual content of the press release dated April 4, 2017 (Exhibit 99.1), as the summary text does not detail the material event.
  • Confirm the registrant name is Galapagos NV, noting the discrepancy with the "Lakefront Biotherapeutics NV" label in the request metadata.
  • Review the referenced Registration Statements (File Nos. 333-211765, 333-204567, 333-208697, 333-211834, and 333-215783) for context on the incorporated information.
  • Check for the excluded quote by Dr. Walid Abi-Saab mentioned in the incorporation clause.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.